Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for RaQualia Pharma's Days Inventory or its related term are showing as below:
TSE:4579'
s Days Inventory Range Over the Past 10 Years
Min: 8.33 Med: 19.03 Max: 116.51
Current: 91.66
During the past 13 years, RaQualia Pharma's highest Days Inventory was 116.51. The lowest was 8.33. And the median was 19.03.
TSE:4579's Days Inventory is ranked better than 72.61% of 639
companies
in the Biotechnology industry
Industry Median: 184.66
vs TSE:4579: 91.66
RaQualia Pharma's Days Inventory
declined
from Jun. 2025 (93.71) to Jun. 2026 (0.00).
Inventory Turnover measures how fast the company turns over its inventory within a year.
RaQualia Pharma's Inventory Turnover for the
three
months ended in Jun. 2026 was 0.00.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
RaQualia Pharma (TSE:4579) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
RaQualia Pharma's Inventory Turnover for the
three
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
RaQualia Pharma's Inventory to Revenue for the
three
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
RaQualia Pharma Days Inventory Related Terms
RaQualia Pharma Days Inventory Historical Data
* Premium members only.
The historical data trend for RaQualia Pharma's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4579 vs VRTX, REGN, MRNA: Days Inventory Comparison
For the Biotechnology subindustry, RaQualia Pharma's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaQualia Pharma Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RaQualia Pharma's Days Inventory distribution charts can be found below:
* The bar in red indicates where RaQualia Pharma's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaQualia Pharma (TSE:4579) has a Days Inventory of 0.00 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on RaQualia Pharma and its competitors. Over the past decade, RaQualia Pharma's Days Inventory has ranged from 8.33 to 116.51. According to the industry distribution chart, RaQualia Pharma ranks #175 out of 639 companies in the Biotechnology industry, placing it in the top 27.4%.
Is RaQualia Pharma's Days Inventory too high?
RaQualia Pharma's current Days Inventory is 0.00. Over the past 10 years, this metric has ranged from a low of 8.33 to a high of 116.51. Based on the distribution chart, RaQualia Pharma ranks #175 out of 639 companies in the Biotechnology industry, which is above the industry midpoint. Overall, RaQualia Pharma has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RaQualia Pharma ranks #175 out of 639 companies for Days Inventory. This puts RaQualia Pharma in the upper half of its industry. The industry median Days Inventory is 184.66. Historically, RaQualia Pharma's own Days Inventory has ranged from 8.33 to 116.51 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 184.66, based on 639 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on RaQualia Pharma and its competitors. For the Biotechnology industry, the median Days Inventory is 184.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaQualia Pharma's current Days Inventory is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Modestly Undervalued. The stock's GF Value™ is 円760.48, compared to a current price of 円550.00 — trading 27.7% below its estimated fair value. The current Days Inventory is 0.00. RaQualia Pharma's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Days Inventory is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaQualia Pharma (TSE:4579) Overvalued in 2026?
Based on GuruFocus' analysis, RaQualia Pharma stock appears to be undervalued.
The current stock price of 円550.00 is trading 27.7% below its estimated GF Value™ of 円760.48.
GuruFocus considers RaQualia Pharma to be Modestly Undervalued.
Key valuation signals for TSE:4579:
Days Inventory: 0.00
GF Value™: 円760.48 vs. price of 円550.00 (27.7% below fair value)
No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
62GF Score
Get the complete analysis for TSE:4579
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4579 has been successfully added to your 
